Update: GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial
February 06, 2020 11:49 ET
|
GeoVax, Inc.
Company Comments on NIH/NIAID Discontinuance of Sanofi/GSK HVTN 702 Trial ATLANTA, GA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX) (OTC: GOVXD), a...
GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine
January 27, 2020 10:18 ET
|
GeoVax, Inc.
ATLANTA, GA, and WUHAN, CHINA, Jan. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVXD), a biotechnology company developing human immunotherapies and vaccines against...
GeoVax Announces Reverse Stock Split
January 23, 2020 09:00 ET
|
GeoVax, Inc.
1:2000 Reverse Split Effective January 24, 2020;Ticker Symbol Changed to GOVXD for 20 Days ATLANTA, GA, Jan. 23, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTC: GOVX) today...